New targeted therapies for advanced prostate cancer
Targeted nanotherapies for the treatment of prostate cancer
['FUNDING_R21'] · WASHINGTON STATE UNIVERSITY · NIH-10947329
This study is exploring a new way to treat advanced prostate cancer using tiny particles that can deliver chemotherapy directly to cancer cells, helping to make the treatment more effective and reduce side effects, and it will test this method with a drug called Cabozantinib.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON STATE UNIVERSITY (nih funded) |
| Locations | 1 site (PULLMAN, UNITED STATES) |
| Trial ID | NIH-10947329 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative nanotechnology-based therapies specifically designed to treat advanced prostate cancer, which is a significant health concern for men. The approach involves creating specialized nanoplatforms that can deliver high doses of chemotherapy directly to cancer cells while minimizing side effects. By targeting a specific protein found on prostate cancer cells, the treatment aims to enhance the effectiveness of existing drugs and improve patient outcomes. The study will utilize a drug called Cabozantinib, which has shown promise in other cancers, to test this new delivery method.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer who have limited treatment options.
Not a fit: Patients with early-stage prostate cancer or those who do not express the targeted protein may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promise in using targeted nanotherapies for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
PULLMAN, UNITED STATES
- WASHINGTON STATE UNIVERSITY — PULLMAN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHARMA, ANJALI — WASHINGTON STATE UNIVERSITY
- Study coordinator: SHARMA, ANJALI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Cause, Cancer Etiology, Cancer Patient, Cancers